Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Milestone Scientific (MLSS) Cash & Equivalents (2016 - 2025)

Milestone Scientific's Cash & Equivalents history spans 16 years, with the latest figure at $1.3 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 71.83% year-over-year to $1.3 million; the TTM value through Sep 2025 reached $1.3 million, down 71.83%, while the annual FY2024 figure was $3.3 million, 10.82% up from the prior year.
  • Cash & Equivalents for Q3 2025 was $1.3 million at Milestone Scientific, up from $1.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $17.0 million in Q1 2021 and bottomed at $1.3 million in Q2 2025.
  • The 5-year median for Cash & Equivalents is $4.8 million (2024), against an average of $7.3 million.
  • The largest annual shift saw Cash & Equivalents surged 2112.96% in 2021 before it crashed 82.81% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $14.8 million in 2021, then crashed by 40.97% to $8.7 million in 2022, then crashed by 65.83% to $3.0 million in 2023, then grew by 10.82% to $3.3 million in 2024, then tumbled by 59.23% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for MLSS's Cash & Equivalents are $1.3 million (Q3 2025), $1.3 million (Q2 2025), and $2.2 million (Q1 2025).